Decision Point One: What You Should Do About Vivitrol

Decision Point One Select what you should do: Vivitrol (naltrexone) injection, 380 mg intramuscularly in the gluteal region every 4 weeks

Mrs. Maria Perez, a 53-year-old Puerto Rican female, presents with a complex history of gambling disorder and alcohol use disorder that has been compounded by recent behavioral changes and financial difficulties. Her situation necessitates a careful evaluation of appropriate pharmacological interventions that address her dual diagnoses while considering her current mental status, substance use history, and comorbid conditions. The main objective at this decision point is to determine the most suitable medication to assist her in maintaining abstinence from alcohol and controlling her gambling behaviors.

Mrs. Perez's history indicates a longstanding problem with alcohol, initiated in her late teens, with recent exacerbations linked to her gambling activities. Her relapse pattern is notably associated with her engagement in high-stakes gambling at the newly opened 'Rising Sun' casino. The pleasurable high she experiences from gambling, coupled with alcohol consumption, suggests a behavioral reinforcement loop that complicates her recovery process. The increase in cigarette smoking and weight gain further underscore her ongoing struggle with impulsivity, self-control, and health management.

From her mental status examination, Mrs. Perez exhibits no current suicidal or homicidal ideation, and her judgment and insight appear grossly intact despite impaired impulse control. Her appearance as alert and oriented with coherent speech suggests that her cognitive status is preserved, but her avoidant eye contact might indicate social anxiety or emotional distress. Her self-reported mood as "sad" aligns with her concern over her financial situation and her health issues. Her impulsivity and difficulty with impulse control imply that pharmacological strategies that aid in reducing cravings and impulsive behaviors could be beneficial.

Pharmacologically, the treatment options include Vivitrol (naltrexone), Antabuse (disulfiram), and Campral (acamprosate). Each has distinct mechanisms and indications for alcohol use disorder, with Vivitrol functioning as an opioid antagonist to reduce cravings, disulfiram causing unpleasant symptoms when alcohol is consumed, and acamprosate modulating glutamate and GABA pathways to support abstinence. Considering the complexity of Mrs. Perez's presentation, her ongoing engagement in high-risk gambling and alcohol use, and her need for a medication that can reduce the reinforcing effects of alcohol, Vivitrol emerges as a particularly appropriate choice.

Paper For Above instruction

Vivitrol (naltrexone) is a long-acting opioid antagonist that has been approved for the treatment of alcohol use disorder (AUD). Its mechanism involves blocking the mu-opioid receptors, thereby decreasing the euphoric and reinforcing effects of alcohol, which in turn reduces cravings and supports abstinence (Garbutt et al., 2005). Furthermore, naltrexone has demonstrated efficacy in reducing alcohol consumption and decreasing the likelihood of relapse in individuals with AUD (O'Malley et al., 2003). In patients like Mrs. Perez, who exhibit impulsive behaviors and a tendency toward compulsive gambling complemented by alcohol use, naltrexone can assist in diminishing the reinforcing properties of alcohol and potentially decrease gambling-related behaviors, especially since gambling and alcohol consumption are often intertwined through shared reward pathways (Leeman & Potenza, 2013).

Research indicates that naltrexone can modulate the brain's reward circuitry, targeting the endogenous opioid system involved in addictive behaviors (Krystal et al., 2001). Its injectable form, Vivitrol, provides a sustained-release mechanism requiring administration once every four weeks, improving compliance, particularly in individuals with poor medication adherence or those who have difficulty maintaining daily medication routines (Fleming et al., 2014). This aspect is especially relevant for Mrs. Perez, who may struggle with routine medications given her impulsivity and recent impulsive financial decisions.

In addition to pharmacological considerations, Vivitrol's side effect profile makes it a suitable option. Common adverse effects include injection site reactions, nausea, headache, and fatigue, but it is generally well tolerated. Notably, Vivitrol does not contain any acetaldehyde-producing agents and does not interfere significantly with alcohol metabolism, allowing for some flexibility during the initial phases of treatment while the patient's tolerance and cravings are evaluated (Kiefer et al., 2003).

Compared to disulfiram, which requires strict adherence to avoid alcohol's adverse effects, Vivitrol provides a more forgiving approach, as its effect persists for four weeks, reducing the risk of deliberate non-compliance. Meanwhile, Campral (acamprosate) acts on glutamate and GABA neurotransmitter systems to reduce physiological cravings but tends to be less effective in individuals with ongoing drinking or relapse risk, and it requires thrice-daily dosing, which can challenge adherence (Mason et al., 2006). This makes Vivitrol advantageous for Mrs. Perez, given her impulsive tendencies and difficulty maintaining routine medication maintenance.

Furthermore, in patients like Mrs. Perez, who may also have co-occurring gambling disorder, Vivitrol's impact on the endogenous opioid system can be beneficial in reducing the compulsivity associated with addictive behaviors (Booth et al., 2015). Although evidence specifically for gambling disorder is emerging, preliminary studies suggest Vivitrol can help diminish gambling urges and reduce associated distress (Grant et al., 2019). Therefore, employing Vivitrol aligns with a broader strategy to address her multiple behavioral health issues simultaneously, with the potential to reduce alcohol consumption, gambling urges, and impulsivity.

In summary, Vivitrol (naltrexone) injection is the preferred option at this decision point due to its efficacy in reducing alcohol cravings, its sustained-release formulation enhancing compliance, and its potential benefits in managing behavioral impulsivity linked to her gambling disorder. Its safety profile, combined with evidence supporting its use in similar contexts, makes it an appropriate pharmacologic intervention for Mrs. Perez’s complex clinical picture.

References

• Booth, K., Roth, M., & Blaszczynski, A. (2015). Pharmacological treatment of gambling disorder: An update. Australian & New Zealand Journal of Psychiatry, 49(8), 683-692.
• Fleming, C. B., McGeary, J. E., et al. (2014). Pharmacotherapy for Alcohol Use Disorder - Systematic Review. Annals of Internal Medicine, 161(3), 251-260.
• Garbutt, J. C., Kranzler, H. R., et al. (2005). Efficacy and tolerability of opiate antagonists for alcohol dependence: A meta-analysis. JAMA, 293(14), 1803-1811.
• Grant, J. E., Odlaug, B. L., et al. (2019). Use of Naltrexone in the treatment of Gambling Disorder. Journal of Clinical Psychiatry, 80(3), 92-98.
• Kiefer, F., et al. (2003). Naltrexone in the treatment of alcohol dependence: A review of clinical trials. Alcohol and Alcoholism, 38(2), 173-180.
• Krystal, J. H., et al. (2001). Naltrexone in the treatment of alcohol dependence: A randomized controlled trial. Archives of General Psychiatry, 58(4), 357-364.
• Leeman, R. F., & Potenza, M. N. (2013). Similarities and differences between pathological gambling and substance use disorders. Drug and Alcohol Dependence, 131(3), 259-273.
• Mason, B. J., et al. (2006). Efficacy of acamprosate in alcohol dependence: A review. Alcoholism: Clinical and Experimental Research, 30(3), 414-423.
• O'Malley, S. S., et al. (2003). Naltrexone and cognitive-behavioral therapy for alcohol dependence. Archives of General Psychiatry, 60(7), 727-735.
• Leeman, R. F., & Potenza, M. N. (2013). Similarities and differences between pathological gambling and substance use disorders. Drug and Alcohol Dependence, 131(3), 259-273.